Circulating miR-200a is a novel molecular biomarker for early-stage renal cell carcinoma

Wang, Cheng; Ding, Meng; Zhu, Yuanyuan; Hu, Jicheng; Zhang, Cuiping; Lu, Xiaolan; Ge, Jingping; Wang, Junjun; Zhang, Chenyu

doi:10.1186/s41544-019-0023-z

Cited by 17 publications

(18 citation statements)

References 43 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiR-200a regulates epithelial to mesenchymal transition-associated with gene expression and regulates prognosis in colorectal cancer [ 27 ]. In addition, miR-200a consistently decreased in RCC and serve as diagnostic biomarker for the early detection of RCC [ 28 ].…”

Section: Resultsmentioning

confidence: 99%

A novel miRNA-based classification model of risks and stages for clear cell renal cell carcinoma patients

et al. 2021

View full text Add to dashboard Cite

Background Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal carcinoma and patients at advanced stage showed poor survival rate. Despite microRNAs (miRNAs) are used as potential biomarkers in many cancers, miRNA biomarkers for predicting the tumor stage of ccRCC are still limitedly identified. Therefore, we proposed a new integrated machine learning (ML) strategy to identify a novel miRNA signature related to tumor stage and prognosis of ccRCC patients using miRNA expression profiles. A multivariate Cox regression model with three hybrid penalties including Least absolute shrinkage and selection operator (Lasso), Adaptive lasso and Elastic net algorithms was used to screen relevant prognostic related miRNAs. The best subset regression (BSR) model was used to identify optimal prognostic model. Five ML algorithms were used to develop stage classification models. The biological significance of the miRNA signature was analyzed by utilizing DIANA-mirPath. Results A four-miRNA signature associated with survival was identified and the expression of this signature was strongly correlated with high risk patients. The high risk patients had unfavorable overall survival compared with the low risk group (HR = 4.523, P-value = 2.86e−08). Univariate and multivariate analyses confirmed independent and translational value of this predictive model. A combined ML algorithm identified six miRNA signatures for cancer staging prediction. After using the data balancing algorithm SMOTE, the Support Vector Machine (SVM) algorithm achieved the best classification performance (accuracy = 0.923, sensitivity = 0.927, specificity = 0.919, MCC = 0.843) when compared with other classifiers. Furthermore, enrichment analysis indicated that the identified miRNA signature involved in cancer-associated pathways. Conclusions A novel miRNA classification model using the identified prognostic and tumor stage associated miRNA signature will be useful for risk and stage stratification for clinical practice, and the identified miRNA signature can provide promising insight to understand the progression mechanism of ccRCC.

show abstract

Section: Resultsmentioning

confidence: 99%

A novel miRNA-based classification model of risks and stages for clear cell renal cell carcinoma patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…miR-200a has been previously related to RCC and has been proposed as biomarker for early stage RCC in serum, urine and RCC cell lines [ 19 ]. In addition, Fedorko et al [ 20 ] also evidenced an increase in let-7d in the urine of ccRCC patients.…”

Section: Discussionmentioning

confidence: 99%

Identification of miR-20a-5p as Robust Normalizer for Urine microRNA Studies in Renal Cell Carcinoma and a Profile of Dysregulated microRNAs

Oto

Herranz

Plana

et al. 2021

IJMS

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is the third most frequent urinary malignancy and one of the most lethal. Current diagnostic and follow-up techniques are harmful and unspecific in low-grade tumors. Novel minimally invasive markers such as urine microRNAs (miRNAs) are under study. However, discrepancies arise among studies in part due to lack of consent regarding normalization. We aimed to identify the best miRNA normalizer for RCC studies performed in urine samples together with a miRNA profile with diagnostic value and another for follow-up. We evaluated the performance of 120 candidate miRNAs in the urine of 16 RCC patients and 16 healthy controls by RT-qPCR followed by a stability analysis with RefFinder. In this screening stage, miR-20a-5p arose as the most stably expressed miRNA in RCC and controls, with a good expression level. Its stability was validated in an independent cohort of 51 RCC patients and 32 controls. Using miR-20a-5p as normalizer, we adjusted and validated a diagnostic model for RCC with three miRNAs (miR-200a-3p, miR-34a-5p and miR-365a-3p) (AUC = 0.65; Confidence Interval 95% [0.51, 0.79], p = 0.043). let-7d-5p and miR-205-5p were also upregulated in patients compared to controls. Comparing RCC samples before surgery and fourteen weeks after, we identified let-7d-5p, miR-152-3p, miR-30c-5p, miR-362-3p and miR-30e-3p as potential follow-up profile for RCC. We identified validated targets of most miRNAs in the renal cell carcinoma pathway. This is the first study that identifies a robust normalizer for urine RCC miRNA studies, miR-20a-5p, which may allow the comparison of future studies among laboratories. Once confirmed in a larger independent cohort, the miRNAs profiles identified may improve the non-invasive diagnosis and follow-up of RCC.

show abstract

“…Wang et al have detected a decreased expression of miR-200a in serum and urinary samples of RCC patients compared to controls [ 98 ].…”

Section: Mirna As a Biomarker Of Rccmentioning

confidence: 99%

The Ambivalent Role of miRNAs in Carcinogenesis: Involvement in Renal Cell Carcinoma and Their Clinical Applications

et al. 2021

View full text Add to dashboard Cite

The analysis of microRNA (miRNAs), small, non-coding endogenous RNA, plays a crucial role in oncology. These short regulatory sequences, acting on thousands of messenger RNAs (mRNAs), modulate gene expression at the transcriptional and post-transcriptional level leading to translational repression or degradation of target molecules. Although their function is required for several physiological processes, such as proliferation, apoptosis and cell differentiation, miRNAs are also responsible for development and/or progression of several cancers, since they may interact with classical tumor pathways. In this review, we highlight recent advances in deregulated miRNAs in cancer focusing on renal cell carcinoma (RCC) and provide an overview of the potential use of miRNA in their clinical settings, such as diagnostic and prognostic markers.

show abstract

Circulating miR-200a is a novel molecular biomarker for early-stage renal cell carcinoma

Cited by 17 publications

References 43 publications

A novel miRNA-based classification model of risks and stages for clear cell renal cell carcinoma patients

A novel miRNA-based classification model of risks and stages for clear cell renal cell carcinoma patients

Identification of miR-20a-5p as Robust Normalizer for Urine microRNA Studies in Renal Cell Carcinoma and a Profile of Dysregulated microRNAs

The Ambivalent Role of miRNAs in Carcinogenesis: Involvement in Renal Cell Carcinoma and Their Clinical Applications

Contact Info

Product

Resources

About